Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab

Dove Medical Press (Taylor and Francis Group) 2026 Open access

Read full text
Authors: lang yu
DOI: 10.6084/m9.figshare.31045027
Cited by: 0

Fields of Study & Subjects

Autoimmune Bullous Skin Diseases Dermatology and Skin Diseases Skin and Cellular Biology Research

Publication details

Journal / source
Dove Medical Press (Taylor and Francis Group)
Publication date
1 January 2026
Language
EN